Fung C P, Yeo S F, Livermore D M
Department of Medical Microbiology, London Hospital Medical College, UK.
J Antimicrob Chemother. 1994 Feb;33(2):215-22. doi: 10.1093/jac/33.2.215.
Moraxella catarrhalis isolates (n = 413) were collected from 20 clinical laboratories in England and Scotland in 1991 and were examined for beta-lactamase production by isoelectric focusing. beta-Lactamases were found in 375 isolates of which, 349 (93.1%) had BRO-1 enzyme and 26 (6.9%) had BRO-2. Minor variation in electrofocusing pattern occurred within both enzyme types. Ampicillin MICs for BRO-1 producers were 25-fold higher than for non-producers, but those for BRO-2 producers were raised only four-fold. MICs of cefaclor, cefixime, loracarbef, co-amoxiclav and cefetamet generally were two- to four-fold higher for BRO-1 producers than for BRO-2 producers and enzyme non-producers. Similarly, the inhibition zones of discs containing cefaclor, cefixime, loracarbef or co-amoxiclav were smaller for BRO-1 producers than for non-producers. Amongst the compounds tested, cefetamet seemed the least affected by beta-lactamase production in both MIC and disc tests. Overall, these results indicate that BRO-1 enzyme predominates amongst M. catarrhalis isolates from the UK, as in other countries, and suggest that BRO-1 production gives slight protection against many of the newer oral beta-lactams as well as causing ampicillin resistance.
1991年,从英格兰和苏格兰的20个临床实验室收集了413株卡他莫拉菌分离株,通过等电聚焦法检测其β-内酰胺酶的产生情况。在375株分离株中发现了β-内酰胺酶,其中349株(93.1%)具有BRO-1酶,26株(6.9%)具有BRO-2酶。两种酶类型内部的电聚焦图谱均出现了微小差异。BRO-1产生菌的氨苄西林最低抑菌浓度(MIC)比非产生菌高25倍,但BRO-2产生菌的仅升高了4倍。头孢克洛、头孢克肟、氯碳头孢、阿莫西林克拉维酸和头孢他美酯的MIC,BRO-1产生菌通常比BRO-2产生菌和酶非产生菌高2至4倍。同样,含头孢克洛、头孢克肟、氯碳头孢或阿莫西林克拉维酸的药敏纸片对BRO-1产生菌的抑菌圈比对非产生菌的小。在测试的化合物中,无论是MIC测试还是药敏纸片测试,头孢他美酯似乎受β-内酰胺酶产生的影响最小。总体而言,这些结果表明,与其他国家一样,BRO-1酶在来自英国的卡他莫拉菌分离株中占主导地位,并且表明产生BRO-1会对许多新型口服β-内酰胺类药物产生轻微抗性,同时导致氨苄西林耐药。